Related Experiment Videos
Effect of TNF priming of murine peritoneal macrophages on their activation to a tumoricidal state
Abstract:
Murine peritoneal macrophages, on treatment with TNF (10 U/ml) for various durations, showed enhanced cyototoxicity against tumor target cells. The macrophage-mediated cytotoxicity was significantly enhanced when TNF-primed macrophages were treated with cisplatin, LPS, FK-565 or interferon-gamma for 24 h, compared to unprimed and treated macrophages. TNF-primed macrophages also showed enhanced expression of interleukin-1 and tumor necrosis factor activities on activation with different biological response modifiers.
Insights
Tumor necrosis factor (TNF) primes macrophages to enhance their cancer-killing ability. Further treatment with agents like cisplatin or interferon-gamma significantly boosts this macrophage-mediated cytotoxicity and cytokine expression.
Area of Science:
- Immunology
- Cancer Biology
- Pharmacology
Background:
- Tumor necrosis factor (TNF) is a key cytokine involved in immune responses and inflammation.
- Macrophages play a crucial role in anti-tumor immunity.
- Enhancing macrophage anti-tumor activity is a therapeutic strategy in cancer treatment.
Purpose of the Study:
- To investigate the effect of TNF priming on macrophage cytotoxicity against tumor cells.
- To evaluate the synergistic effects of TNF-primed macrophages with other biological response modifiers (BRMs).
- To assess the impact of BRMs on the expression of interleukin-1 (IL-1) and TNF in primed macrophages.
Main Methods:
- Murine peritoneal macrophages were treated with TNF (10 U/ml) for varying durations.
- TNF-primed macrophages were subsequently treated with cisplatin, lipopolysaccharide (LPS), FK-565, or interferon-gamma (IFN-γ) for 24 hours.
- Macrophage-mediated cytotoxicity against tumor target cells was assessed.
- Expression levels of IL-1 and TNF activities in activated macrophages were measured.
Main Results:
- TNF treatment alone enhanced macrophage cytotoxicity against tumor cells.
- Co-treatment of TNF-primed macrophages with cisplatin, LPS, FK-565, or IFN-γ significantly increased macrophage-mediated cytotoxicity compared to unprimed, treated macrophages.
- TNF-primed macrophages exhibited enhanced expression of IL-1 and TNF activities upon activation with various BRMs.
Conclusions:
- TNF priming effectively enhances the intrinsic anti-tumor cytotoxicity of macrophages.
- Combining TNF priming with specific BRMs like cisplatin, LPS, FK-565, and IFN-γ synergistically augments macrophage anti-tumor functions.
- This study highlights a potential strategy for enhancing immunotherapy by modulating macrophage activity and cytokine production.